Bartosz Rymuza
Overview
Explore the profile of Bartosz Rymuza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gasecka A, Gniot M, Rajewska B, Dykacz W, Kisielewska W, Blazejowska E, et al.
Cardiol J
. 2025 Mar;
PMID: 40062926
Background: Intestinal microbial metabolites, such as trimethylamine-N-oxide (TMAO) and indoxyl sulfate (IS), have been suggested as markers for the progression of aortic stenosis (AS). However, the impact of transcatheter aortic...
2.
Grodecki K, Pawlak K, Grodecka M, Rymuza B, Scislo P, Ciepiela O, et al.
J Cardiovasc Dev Dis
. 2025 Feb;
12(2).
PMID: 39997496
Subclinical leaflet thrombosis is an imaging phenomenon observed after transcatheter aortic valve implantation (TAVI) and characterized by hypoattenuating leaflet thickening (HALT) on computed tomography angiography. The clinical implications and underlying...
3.
Wilimski R, Budzianowski J, Lomiak M, Olasinska-Wisniewska A, Pieniak K, Jedrzejczyk S, et al.
J Cardiovasc Transl Res
. 2024 May;
17(5):992-1003.
PMID: 38807003
Introduction: Transcatheter aortic valve implantation (TAVI) is an established treatment for aortic stenosis (AS) in patients at intermediate and high surgical risk. Circulating extracellular vesicles (EVs) are nanoparticles involved in...
4.
Wilimski R, Huczek Z, Krauz K, Rymuza B, Mazurek M, Scislo P, et al.
Postepy Kardiol Interwencyjnej
. 2023 Oct;
19(3):243-250.
PMID: 37854973
Introduction: Coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis (AS) referred for transcatheter aortic valve implantation (TAVI) raises questions regarding the safety and efficacy of TAVI...
5.
Walczewski M, Gasecka A, Witkowski A, Dabrowski M, Huczek Z, Wilimski R, et al.
Postepy Kardiol Interwencyjnej
. 2023 Oct;
19(3):251-256.
PMID: 37854972
Introduction: Data regarding patients with a previous medical record of immunosuppression treatment who have undergone transcatheter aortic valve implantation (TAVI) are limited and extremely inconclusive. Available studies are mostly short...
6.
Huczek Z, Mazurek M, Kochman J, Kralisz P, Jagielak D, Sacha J, et al.
Kardiol Pol
. 2023 Apr;
81(6):606-612.
PMID: 37096948
Background: Valve-in-valve transcatheter transfemoral mitral valve implantation (ViV-TMVI) is an emerging treatment alternative to reoperation in high-surgical risk patients with failed mitral bioprostheses. Aim: We aimed to describe the characteristics...
7.
Machine learning for prediction of all-cause mortality after transcatheter aortic valve implantation
Kwiecinski J, Dabrowski M, Nombela-Franco L, Grodecki K, Pieszko K, Chmielak Z, et al.
Eur Heart J Qual Care Clin Outcomes
. 2023 Jan;
9(8):768-777.
PMID: 36637410
Aims: Prediction of adverse events in mid-term follow-up after transcatheter aortic valve implantation (TAVI) is challenging. We sought to develop and validate a machine learning model for prediction of 1-year...
8.
Wilimski R, Huczek Z, Grodecki K, Kochman J, Rymuza B, Wojakowski W, et al.
Kardiol Pol
. 2023 Jan;
81(4):373-380.
PMID: 36594529
Background: The carotid artery is an alternative access route for transcatheter aortic valve implantation (TAVI), especially useful in patients unsuitable for traditional access routes including transfemoral (TF), subclavian, transapical, and...
9.
Mazurek M, Rymuza B, Scislo P, Kochman J, Grabowski M, Huczek Z
Kardiol Pol
. 2022 Dec;
81(2):198-199.
PMID: 36573606
No abstract available.
10.
Eyileten C, Skrobucha A, Starczynski M, Boszko M, Jarosz-Popek J, Fitas A, et al.
Cardiol J
. 2022 Oct;
31(1):111-123.
PMID: 36200549
Background: Transcatheter aortic valve implantation (TAVI) is an established treatment for aortic stenosis (AS) in patients at increased surgical risk. Up to 29% of patients annually experience major adverse cardiac...